SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (472)12/12/2003 10:49:29 AM
From: Arthur Radley  Read Replies (1) | Respond to of 631
 
COPENHAGEN, Dec 12 (Reuters) - Danish biotech firm Genmab (Copenhagen:GEN.CO - News) said on Friday it planned to drop the development of a drug for the treatment of psoriasis after tests showed no significant results, sending its shares down as much as 17.7 percent.


Genmab said a clinical Phase 2 study of 118 patients did not achieve statistically significant results.